Press releases
Read press releases issued by GlaxoSmithKline Pharmaceuticals Limited.
Our Global press releases can be viewed on our global website.
-
GSK and Yuva Unstoppable Transform Education with 100th Smart Classroom in Nashik
GSK and Yuva Unstoppable Transform Education with 100th Smart Classroom in Nashik
-
Most people over 50 in India unaware of shingles disease, despite being at risk¹
Most people over 50 in India unaware of shingles disease, despite being at risk
-
GlaxoSmithKline Pharmaceuticals Limited (GSK) Delivers Strong Q3 Performance with Double-Digit Growth
GlaxoSmithKline Pharmaceuticals Limited (GSK) Delivers Strong Q3 Performance with Double-Digit Growth
-
GlaxoSmithKline Pharmaceuticals Limited crosses Rs.1000 crore in Revenue from Operations
GlaxoSmithKline Pharmaceuticals Limited crosses Rs.1000 crore in Revenue from Operations
-
"Yeh Science Hai": Amitabh Bachchan and Manoj Pahwa partner with GSK for new shingles awareness and prevention campaign
GSK today launched a new campaign on Shingles awareness, featuring veteran actors Amitabh Bachchan and Manoj Pahwa
-
GlaxoSmithKline Pharmaceuticals Limited Reports Continued Growth and Profitability for the Quarter
Revenue from operations for the quarter grew by 10% at INR 811 crores. Profit After Tax (PAT) for the quarter at INR 182 crores.
-
GSK's new campaign asks parents to support their children's future with 7 crucial vaccinations
GSK today announced the launch of its new multichannel campaign 'Ab India Banega 7-Star.'
-
GlaxoSmithKline Pharmaceutical Limited Reports Strong Double-Digit Growth and improved profitability for the quarter
GlaxoSmithKline Pharmaceutical Limited Reports Strong Double-Digit Growth and improved profitability for the quarter
-
Data at the end of a long-term study shows Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
Data at the end of a long-term study shows Shingrix continues to provide high protection against shingles in adults aged 50 and over
-
GlaxoSmithKline Pharmaceuticals Limited (GSK) announces its financial results for the third quarter ended 31st December 2023
GlaxoSmithKline Pharmaceuticals Limited (GSK) announces its financial results for the third quarter ended 31st December 2023
-
GSK registers 5% Growth
General Medicine grows 5% and Vaccines 10% led by Shingrix
-
General Medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business
General Medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business
-
Amitabh Bachchan partners with GSK for shingles awareness and prevention
Amitabh Bachchan partners with GSK for shingles awareness and prevention
-
GlaxoSmithKline Pharmaceuticals Limited reported improved profitability with continued momentum across General medicines and Specialty; Declares annual dividend of Rs. 32
GlaxoSmithKline Pharmaceuticals Limited reported improved profitability with continued momentum across General medicines and Specialty
-
GSK launches Shingrix in India- A vaccine for the prevention of shingles in adults aged 50 years and above
GSK launches Shingrix in India- A vaccine for the prevention of shingles in adults aged 50 years and above
-
Continued momentum across General Medicines and Specialty
Continued momentum across General Medicines and Specialty
-
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2022
GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2022
-
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
-
Media release: Q1 of 2022-23
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2022
